Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000540283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Da Shang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China, shangda@fudan.edu.cn. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Spironolactone, Mineralocorticoid Receptor Antagonists, Proteinuria. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
It′s crucial to utilize combination therapy for IgAN patients to reduce proteinuria and maintain stable kidney function. We demonstrate the safety and efficacy of low-dose spironolactone in management of IgAN patients.
Methods
Adult IgAN patients treated with spironolactone were evaluated. Patients were separated into two categories according to whether 24h-proteinuria was reduced by more than 20% after two-months of spironolactone treatment compared to baseline levels.
Results
88 patients were analyzed and 24h-proteinuria decreased from 0.93g to 0.70 g (p<0.001) after two-months of treatment with spironolactone, accompanied by a slight decrease in EPI-eGFR from 75.7 to 73.9 mL/min/1.73 m2 (p = 0.033). Intriguingly, 47 patients in effective MRA group showed less endocapillary hypercellularity (p = 0.040). In ineffective group, 18 patients discontinued MRA treatment because of 24h-proteinuria increased from 0.83 g to 1.04 g, while the other 23 patients were continued with spironolactone and proteinuria decreased to 0.57 g in the sixth month (p = 0.001). Furthermore, 12 patients with persistent high proteinuria during prednisone therapy, were added with spironolactone. 24-proteinuria were dropped from 0.95 g to 0.73 g at the second month, and to 0.50 g at the sixth month.
Conclusions
In our study, we confirmed spironolactone's efficacy in reducing urine protein excretion in IgA nephropathy patients within two months of treatment. However, response varied among patients, with those showing endocapillary proliferation (E1) in renal biopsies having poor spironolactone responsiveness. Administering mineralocorticoid receptor antagonists (MRAs) to patients with eGFR over 30 ml/min did not result in hyperkalemia, indicating the treatment's safety. Key Words:IgA Nephrology, Proteinuria, Spironolactone, Renal function
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China, shangda@fudan.edu.cn.
- Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Zitieren
APA
Shang, D., Guan, Y., Liu, S., Hao, C., & Lai, L. (2024). Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study. Kidney and Blood Pressure Research. https://doi.org/10.1159/000540283
Vancouver
Shang D, Guan Y, Liu S, Hao C, Lai L. Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study. Kidney and Blood Pressure Research. 2024. doi:10.1159/000540283
BibTeX
@article{Shang2024,
author = {Shang, Da and Guan, Yi and Liu, Shaojun and Hao, ChuanMing and Lai, Lingyun},
title = {Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000540283}
}
EUVIMED